TIBCO Expands Strategic Spotfire Relationship with PerkinElmer to Include Clinical Research and Development Market
PerkinElmer Gains Exclusive Rights to the Global Clinical Research and Development Market
TIBCO Software Inc. (NASDAQ: TIBX), the provider of TIBCO Spotfire®, a leading analytics and data discovery platform, today announced it has expanded its relationship with PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment, a year after previously launching their successful scientific research and development relationship.
The expanded alliance will allow customers to benefit from substantially larger investments in product and application development from PerkinElmer, fostering collaboration and integration between discovery research and clinical development. The early success that PerkinElmer has had in the Global Research Market (GRM) has evolved into an industry benchmark that necessitates applications that provide out-of-the-box functionality. This relationship not only addresses those needs, but serves the increasing interest in the translational approach to medicine.
"We are extremely excited by a part of this unique relationship with PerkinElmer," said Matt Quinn, chief technology officer, TIBCO. "Joining forces strengthens our vertical industry focus on pharmaceuticals and biotech – as well as many others – while giving TIBCO the means and capacity to focus on, and successfully invest in, expansion into other verticals and horizontals."
"Through this expanded strategic relationship, we are very excited to offer scientists a complete package of data generation, data management, plus data analysis and visualization, so they can better harness information for more informed insights and decisions in the clinical space," said Mike Stapleton, general manager, informatics, PerkinElmer. "TIBCO Spotfire complements PerkinElmer's informatics offerings by adding search and data visualization, which are among life science laboratories' most pressing business needs."
Additionally, within this relationship, PerkinElmer becomes the exclusive TIBCO channel for TIBCO Spotfire in clinical research and development applications, including the testing (clinical trials, studies and research) of human populations to determine the safety and efficacy of medications, devices, diagnostic products and treatment regimens, pre-approval (phases 1-3) and post-approval (phase 4) clinical trials, operational data on trial execution, safety risk monitoring (pre and post marketing pharmacovigilance), and adverse event tracking.
For more information on this relationship and TIBCO Software Inc., please visit the www.tibco.com.
PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The company reported revenue of approximately $2.1 billion in 2012, has about 7,500 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.
TIBCO Software Inc. (NASDAQ: TIBX) is a provider of infrastructure software for companies to use on-premise or as part of cloud computing environments. Whether it's optimizing claims, processing trades, cross-selling products based on real-time customer behavior, or averting a crisis before it happens, TIBCO provides companies the Two-Second Advantage® – the ability to capture the right information at the right time and act on it preemptively for a competitive advantage. More than 4,000 customers worldwide rely on TIBCO to manage information, decisions, processes and applications in real time. Learn more at www.tibco.com.
TIBCO, TIBCO Software, Spotfire and Two-Second Advantage are trademarks or registered trademarks of TIBCO Software Inc. or its subsidiaries in the United States and/or other countries. Other product and company names and marks mentioned in this document are the property of their respective owners and are mentioned for identification purposes only.